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Abstract
Background: Long-term immune reconstitution on antiretroviral therapy (ART) has important implications for HIV-infected
children, who increasingly survive into adulthood. Children’s response to ART differs from adults’, and better descriptive and
predictive models of reconstitution are needed to guide policy and direct research. We present statistical models
characterising, qualitatively and quantitatively, patterns of long-term CD4 recovery.
Methods and Findings: CD4 counts every 12 wk over a median (interquartile range) of 4.0 (3.7, 4.4) y in 1,206 HIV-infected children,
aged 0.4–17.6 y, starting ART in the Antiretroviral Research for Watoto trial (ISRCTN 24791884) were analysed in an exploratory analysis
supplementary to the trial’s pre-specified outcomes. Most (n= 914; 76%) children’s CD4 counts rose quickly on ART to a constant age-
corrected level. Using nonlinear mixed-effects models, higher long-term CD4 counts were predicted for children starting ART younger,
and with higher CD4 counts (p,0.001). These results suggest that current World Health Organization–recommended CD4 thresholds for
starting ART in children $5 y will result in lower CD4 counts in older children when they become adults, such that vertically infected
children who remain ART-naı¨ve beyond 10 y of age are unlikely ever to normalise CD4 count, regardless of CD4 count at ART initiation.
CD4 profiles with four qualitatively distinct reconstitution patterns were seen in the remaining 292 (24%) children. Study limitations
included incomplete viral load data, and that the uncertainty in allocating children to distinct reconstitution groups was not modelled.
Conclusions: Although younger ART-naı¨ve children are at high risk of disease progression, they have good potential for
achieving high CD4 counts on ART in later life provided ART is initiated following current World Health Organization (WHO),
Paediatric European Network for Treatment of AIDS, or US Centers for Disease Control and Prevention guidelines. In contrast,
to maximise CD4 reconstitution in treatment-naı¨ve children.10 y, ART should ideally be considered even if there is a low risk
of immediate disease progression. Further exploration of the immunological mechanisms for these CD4 recovery profiles
should help guide management of paediatric HIV infection and optimise children’s immunological development.
Please see later in the article for the Editors’ Summary.
Citation: Picat M-Q, Lewis J, Musiime V, Prendergast A, Nathoo K, et al. (2013) Predicting Patterns of Long-Term CD4 Reconstitution in HIV-Infected Children
Starting Antiretroviral Therapy in Sub-Saharan Africa: A Cohort-Based Modelling Study. PLoS Med 10(10): e1001542. doi:10.1371/journal.pmed.1001542
Academic Editor: Steven G. Deeks, San Francisco General Hospital, United States of America
Received July 17, 2012; Accepted September 12, 2013; Published October 29, 2013
Copyright:  2013 Picat et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: ARROW is funded by the UK Medical Research Council and the UK Department for International Development (DFID). ViiV Healthcare/GlaxoSmithKline
donates first-line drugs for ARROW. JL was supported by an Engineering and Physical Sciences Research Council Life Sciences Interface Doctoral Training Centre
studentship at the Centre for Mathematics and Physics in the Life Sciences and Experimental Biology (CoMPLEX), and also received support from the National
Institute for Health Research Biomedical Research Centre Funding Scheme at Great Ormond Street Hospital and the Institute of Child Health. NK was partly
supported by Great Ormond Street Hospital Charity. The work was also supported by funding from an MRC Grant G1001190. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: AJP is a coinvestigator on the ARROW trial but did not receive any funds for his participation in this trial. AJP is a member of the WHO
paediatric ARV working group but receives no financial support for this activity. AJP is funded by the Wellcome Trust. All other authors have declared that no
competing interests exist.
Abbreviations: ARROW, Antiretroviral Research for Watoto; ART, antiretroviral therapy; CDM, clinically driven monitoring; IQR, interquartile range; LCM,
laboratory and clinical monitoring; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio.
* E-mail: joanna.lewis@ucl.ac.uk
. These authors contributed equally to this work.
" These authors are joint senior authors on this work.
` Membership of the ARROW Trial Team is listed in the Acknowledgments.
PLOS Medicine | www.plosmedicine.org 1 October 2013 | Volume 10 | Issue 10 | e1001542
Introduction
By December 2011, an estimated 3.3 million children under
15 y of age were living with HIV worldwide, over 90% of whom
lived in sub-Saharan Africa [1]. While the 28% coverage of
antiretroviral therapy (ART) for children in need lags behind the
58% coverage in adults, the number of HIV-infected children
receiving ART has nevertheless increased to around 563,000, of
whom 88% are in sub-Saharan Africa. Most receive ART under a
public health approach with little, if any, laboratory monitoring
[2,3]. Current guidelines recommend initiation of ART at age-
related CD4 thresholds that are based on the risk of short-term
disease progression. However, with increasing likelihood of
survival into adulthood, a major challenge is to better understand
how timing of ART initiation in childhood influences long-term
immune reconstitution and immunological health [3]. To date,
studies describing ART outcomes in resource-limited settings have
usually reported only short-term (,1–2 y) disease progression and
CD4 changes as outcomes [2,4]. Studies of longer-term immune
reconstitution after ART initiation are scarce, and have typically
included fewer than 200 children [5–8].
Although some large studies have assessed the long-term
immunological effects of ART in adults in resource-limited settings
[9,10], immune reconstitution differs significantly in children [11–
14], most likely as a result of their more active thymopoiesis [15–
17]. Successful approaches for studying long-term immune
reconstitution in adults [18], and the conclusions drawn, may
therefore not extend to children, and particularly not across all age
groups in childhood. In addition, factors such as greater burden of
co-infections and higher rates of malnutrition may result in
differences in CD4 response between children in well-resourced
and resource-limited settings.
We previously developed a statistical model for CD4 reconsti-
tution in 127 European/South American HIV-infected children
starting ART [19]. It assumes that the rate of increase in CD4
count (standardised for age) is fastest immediately following
treatment initiation, falling exponentially with treatment duration
so that CD4 count tends to a constant value in the long term,
ideally approaching the count in a healthy child of the same age.
By incorporating factors including age at treatment initiation in
our model, we found that current guidelines for ART initiation,
which are designed to reduce short-term risk of disease progres-
sion, may not always be optimal in terms of long-term immune
reconstitution.
With the aim of understanding the kinetics of long-term CD4
reconstitution, we have investigated a large cohort of HIV-
infected, ART-naı¨ve children initiating ART in Uganda and
Zimbabwe and followed up for a median (interquartile range
[IQR]) 4.0 (3.7, 4.4) y. We identified qualitatively different CD4
recovery profiles using linear and nonlinear regression. We also
present predictive models of long-term CD4 status based on age
and CD4 count at ART initiation, constructed using nonlinear
mixed-effects models. By taking into consideration long-term
immunological health, this approach should better inform
decisions for ART initiation, which to date have been based
mainly on risks of short-term disease progression in untreated
children before the era of ART.
Methods
Participants and Follow-Up
We used data from the Antiretroviral Research for Watoto
(ARROW) trial, an open-label, randomised 5-y paediatric trial
comparing two monitoring strategies during first-line ART
(http://www.arrowtrial.org/; ISRCTN 24791884 [20]). 1,206
HIV-infected, ART-naı¨ve children aged 3 mo to 18 y and
meeting WHO criteria for ART were enrolled at three centres
in Uganda (Joint Clinical Research Centre, Paediatric Infectious
Diseases Centre, and Medical Research Council/Uganda Virus
Research Institute Uganda Research Unit on AIDS) and one in
Zimbabwe (University of Zimbabwe, Harare). The trial was
approved by research ethics committees in Uganda, Zimbabwe,
and the United Kingdom. Written informed consent was obtained
from children’s parents/guardians, and written assent from the
children as appropriate.
The ARROW trial’s primary aim was to compare two
monitoring strategies in children starting ART. Accordingly,
children were randomised to either the ‘‘clinically driven
monitoring’’ (CDM) or ‘‘laboratory and clinical monitoring’’
(LCM) group. In both groups, children had a routine full blood
count, lymphocyte subsets (CD4, CD8), and liver and renal
function tests (bilirubin, urea, creatinine, aspartate transaminase,
alanine transaminase) performed every 12 wk. Demographic (age,
sex) and clinical (WHO staging, height, weight) data were also
collected. An additional week 4 lymphocyte subset measurement
was available in children participating in an immunology
substudy. In the CDM group, test results were returned to the
clinician only if he or she requested them for clinical reasons, or
for a grade 4 adverse event as defined in the trial protocol [21]. No
total lymphocyte or CD4 counts were ever returned for CDM
participants. Independently of monitoring randomisation, all
children were also randomised to one of three first-line ART
strategies. A control group (Arm A) received two nucleoside
reverse transcriptase inhibitor (NRTI) drugs (lamivudine and
abacavir) with one non-nucleoside reverse transcriptase inhibitor
(NNRTI)—nevirapine in children aged ,3 y and either nevir-
apine or efavirenz for older children based on clinician choice—
according to WHO guidelines. The remaining children received
these three drugs and also a third NRTI, zidovudine. After 36 wk,
children who had started four-drug ART dropped either
zidovudine (Arm B) or their NNRTI (nevirapine or efavirenz;
Arm C). Criteria for failure of first-line ART and switch to second-
line ART were clinical in both monitoring groups, or immuno-
logical in the LCM group only, and followed WHO guidelines [3].
Participants were followed under these monitoring/ART strategies
until the end of the overarching ARROW trial on 16 March 2012.
No HIV viral loads were assayed in real time, following national
guidelines, although samples were stored, and retrospective testing
was carried out at a subset of time points and in a subset of
children to address specific focussed questions [20]. The sampling
design involved running assays for samples taken at 0, 4, 24, 36,
48, and 144 wk after ART initiation in all children aged ,5 y at
enrolment, plus in older children enrolled after 1 June 2008 and
participating in the immunology substudy (assays 70% complete).
Samples were also assayed at the time of a secondary randomisa-
tion to once versus twice daily lamivudine+abacavir, and 48 and
96 wk subsequently (assays 95% complete), and at 36, 48, and
84 wk in 41 children enrolled in a pharmacokinetic substudy of
once versus twice daily lamivudine+abacavir (assays 100%
complete). One centre also systematically performed viral load
assays in all children as they exited the trial (i.e., did not select
according to possible failure). In children for whom some post-
enrolment viral loads were available, we characterised virological
response to ART by calculating the mean log10 viral load (in RNA
copies/millilitre) (‘‘average log-viral load’’) and the proportion of a
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child’s viral load measurements that were above 80 RNA copies/
ml (‘‘proportion of viral loads detectable’’).
The primary and secondary randomised comparisons have
been reported separately [20]. This analysis is exploratory, was not
specified in the protocol, and was conducted with the aim of
understanding and modelling qualitatively different patterns of
immune reconstitution.
Age-Adjusted CD4 Count
CD4 T cell counts were adjusted for age by dividing by the CD4
count that would be expected in HIV-uninfected children of the
same age [22,23]. Thus, a ratio (‘‘CD4-for-age’’) of 1 indicates the
expected CD4 count for age, and ratios ,1 indicate a lower than
expected CD4 count for age. The CD4 z-score (normalised centile
of the observed CD4 count within a reference population of
uninfected, HIV-exposed children of the same age) [24] was not
used here because z-scores do not allow the youngest children to
have extremely low scores (e.g., 1 CD4 cell/ml has z-score 28.1 in
a 1-y-old, but 262 in a 10-y-old), and the z-score is also very
sensitive to small errors in CD4 count at low values (Figure S1).
Although CD4 percentage is more stable with age and has been
widely used [25,26], CD4 count has been shown to have greater
prognostic value [27] and so was the preferred variable in this
analysis.
Statistical Analyses
Our mathematical model, which assumes nonlinear CD4-for-
age recovery over time, tending towards a final stable level
(asymptote) in the long term, has been previously described [19]. It
is summarised as follows for CD4-for-age in child i at time tij:
ln CD4-for-ageij
 
~asyi{ asyi{intið Þexp {ci tij
  ð1Þ
The child-specific intercept (inti) is the ln(CD4-for-age) value at
treatment initiation. The asymptote (asyi) is the long-term ln(CD4-
for-age) value. The proportional recovery rate ci characterises the
time for recovery, with ln(2)/c being the time for half the total
recovery from int to asy to occur (illustrated in Figure 1).
Transformation of CD4-for-age onto the log scale improves
normality.
Identifying children with asymptotic CD4 reconstitution
profiles. In preliminary analysis we found that the model did
not converge onto the entire dataset. To identify children whose
CD4-for-age trajectories followed Equation 1 (‘‘asymptotic recon-
stitution’’), each child’s CD4 counts were modelled individually,
using least squares to fit each child’s data to Equation 1. Children
were divided into two groups: one in which the least-squares fit
had converged, and the other in which it had not. The first group
thus consisted of children with asymptotic reconstitution, while the
other comprised children with qualitatively different CD4
reconstitution profiles.
Modelling asymptotic reconstitution profiles. In the
group with asymptotic CD4 reconstitution, recovery was analysed
using nonlinear mixed-effects models for ln(CD4-for-age), based
on Equation 1. The mixed-effects model assumes that in each
child the values of the three parameters int, asy, and c are the sum
of a fixed effect—which describes the average response in the
whole population of children with asymptotic reconstitution—and
a normally distributed random effect—which accounts for and
describes inter-individual variability. A normally distributed error
term eij is added to Equation 1 to represent noise, measurement
error, and model mis-specification.
We investigated the predictive value of age, sex, WHO disease
stage, height- and weight-for-age z-scores at ART initiation, and
randomisation to monitoring and first-line ART strategies on
proportional recovery rate (c) and CD4-for-age at ART initiation
(int) and in the long term (asy), using a backwards-selection
procedure based on an exit p = 0.01 to favour parsimony and
avoid including small significant but clinically unimportant effects
given the size of the dataset. Height- and weight-for-age z-scores
were calculated using UK norms, which, unlike WHO references,
cover the whole childhood age range [28].
Characterising non-asymptotic reconstitution. In chil-
dren without asymptotic CD4 reconstitution, we used linear
models to fit CD4-for-age trajectories and identify those with
increasing or decreasing CD4-for-age, those in whom CD4-for-age
did not change significantly, and those with insufficient data to
characterise a recovery profile.
Analyses were performed in R [29], using the nlme package
[30] for nonlinear modelling. Graphs interpreting the fitted
parameter values in terms of predicted CD4 trajectories were
produced using Mathematica [31].
Results
1,206 ART-naı¨ve children (51% girls) were enrolled in the
ARROW trial between 15 March 2007 and 18 November 2008
and followed for a median (IQR) 4.0 (3.7, 4.4) y. 806 (67%) were
from Uganda; 400 (33%) were from Zimbabwe. There were 600
children in the LCM group versus 606 children in the CDM group
in the monitoring randomisation, and 397 children in Arm A (198
LCM, 199 CDM) versus 404 in Arm B (201 LCM, 203 CDM)
versus 405 in Arm C (201 LCM, 204 CDM) in the ART strategy
randomisation.
Median (IQR) age at ART initiation was 6.0 (2.4, 9.3) (range:
0.4–17.6) y, and the median (IQR) CD4 count and CD4-for-age
were 360 (164, 694) cells/ml and 0.28 (0.14, 0.43), respectively. At
ART initiation, 683 (57%) and 169 (14%) children were at WHO
disease stage 3 and 4, respectively. Children were moderately
wasted (median [IQR] weight-for-age z-score 22.2 [23.3, 21.3])
and stunted (median [IQR] height-for-age z-score 22.4 [23.4,
21.5]).
At least one post-enrolment viral load measurement was
available in 950 children (79%), who had a median (IQR) age of
4.4 (2.0, 7.7) y, a median CD4 count of 439 (197, 780) cells/ml,
and a median CD4-for-age of 0.29 (0.16, 0.46) at ART initiation.
In these 951 children, the median (IQR) number of measurements
Figure 1. An illustrative representation of the mathematical
model used to describe CD4 reconstitution.
doi:10.1371/journal.pmed.1001542.g001
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per child was 4 (3, 7), and samples were collected after a median
(IQR) 84 (36, 144) wk on ART.
Contrasting Long-Term Profiles of CD4 Reconstitution
Following ART Initiation
Our model identified two distinct groups according to long-term
CD4 reconstitution profiles on ART. The first group included 914
(76%) children with asymptotic CD4 reconstitution (average
response in this group shown in Figure 2B). Among the remaining
292 (24%) children, CD4-for-age values followed qualitatively
different trajectories. At ART initiation, children with asymptotic
reconstitution were younger (p,0.001) and had lower CD4-for-
age (p,0.001) and height-for-age z-score (p,0.001) (Table 1). In
multivariable logistic models, experiencing asymptotic reconstitu-
tion was independently associated with being younger at ART
initiation (odds ratio [OR] [95% CI] = 0.94 [0.91, 0.97] per year
older, p,0.001) and having lower height-for-age (OR = 0.86 [0.78,
0.95] per unit higher height-for-age, p = 0.003). Children rando-
mised to four-drug, two-class induction followed by two-
NRTI+NNRTI maintenance (Arm B) were more likely to have
asymptotic reconstitution than the standard-of-care arm (Arm A)
(OR = 1.48 [1.05, 2.07] higher, p = 0.024), but there was no
evidence of a difference between three-NRTI maintenance (Arm
C) and Arm A (OR = 0.93 [0.68, 1.28] higher, p = 0.65). Notably,
monitoring strategy (CDM versus LCM) did not predict allocation
to asymptotic or non-asymptotic reconstitution groups before
(p = 0.61, Table 1) or after adjustment for other factors
(OR[CDM:LCM] = 0.93 [0.71, 1.21], p = 0.57).
Clinically, children with non-asymptotic recovery showed
generally worse disease progression than those with asymptotic
recovery. 42 (14%) as opposed to 21 (2.3%) switched to second-
line therapy (OR 7.13 [4.04, 12.92], p,0.001) (none in the first
year on ART), and 53 (18%) versus 59 (6.5%) experienced WHO
stage 3 or 4 HIV events (OR 3.21 [2.11, 4.87], p,0.001).
Post-enrolment viral loads were available in 750 (82%) of the
children with asymptotic reconstitution (median [IQR] 4 [3, 7]
values available per child) and 200 (68%) of the children with non-
asymptotic reconstitution (median [IQR] 3 [2, 6] values available
per child). There was some marginal evidence of poorer virological
response to ART in the non-asymptotic responders: median (IQR)
average log-viral load was 2.07 (1.90, 3.45) compared to 2.03
(1.90, 2.39) in asymptotic responders (p = 0.050), and the
proportion of viral loads detectable (.80 copies/ml) was 0.33
(0.00, 1.00) compared to 0.25 (0.00, 0.50) (p = 0.014).
Children with Asymptotic CD4 Reconstitution
Figure 2A shows mean CD4-for-age throughout follow-up in
this group, who had a median (IQR) age of 5.6 (2.3, 9.0) y and a
median (IQR) CD4 count of 345 (176, 655) cells/ml at ART
initiation (Table 1). Table 2 gives population average (fixed-effects)
parameters as fitted in the nonlinear mixed-effects model, and
Figure 2B and 2C illustrate the impact of age on expected CD4-
for-age trajectory. There was no evidence of nonlinearity in the
relationships between age at ART initiation and CD4 count either
at ART initiation or in the long term. From the model, the
estimated median (IQR) CD4 count in this group after 3.9 y on
ART was 903 (658, 1,281) cells/ml. The proportional recovery
rate, c, was 0.038 (95% CI: 0.036, 0.040) per week, corresponding
to a half-life t1/2 = ln(2)/c (the time taken for half of the ultimate
on-ART increase in CD4-for-age from intercept to asymptote to
occur) of 18 (95% CI: 17, 19) wk.
A strong correlation was estimated between CD4-for-age at
ART initiation and in the long term (correlation [95% CI] = 0.37
[0.31, 0.43], p,0.001; Figure 2D): that is, children who started
ART with higher CD4-for-age achieved higher CD4-for-age in
the long term. Interestingly, children with lower CD4-for-age at
ART initiation had faster initial recovery (correlation =20.35
[20.43, 20.27], p,0.001; Figure 2D). These two correlations
combined so that those with faster initial recovery also ended up
with lower long-term CD4-for-age (correlation =20.44 [20.54,
20.33], p,0.001; Figure 2D). Such results are consistent with
reconstitution processes that are sensitive to a low concentration of
CD4 T cells, driving faster recovery in response to lower CD4-for-
age, but that are nonetheless unable to reverse significant HIV-
related impairment, which is reflected in lower CD4-for-age both
before and after treatment. The second important observation was
that in multivariable analyses (Table 2), lower CD4-for-age at
ART initiation and in the long term were each independently
associated with older age at ART initiation (both p,0.001;
Figure 2B). Lower CD4-for-age at ART initiation was also
associated with lower weight-for-age z-score (p,0.001). Boys
achieved lower long-term CD4-for-age values than girls, as did
children randomised to zidovudine-containing three-NRTI main-
tenance (Arm C) compared to those in Arm A (both p,0.001).
Using backwards selection, we found no covariates whose
inclusion in the model for proportional recovery rate c substan-
tially improved the fit.
Because CD4 counts in adults starting ART have often been
fitted using linear mixed-effects models with a change in slope
some weeks after treatment initiation [18], we fitted a similar
model in our CD4-for-age data. It proved a substantially worse fit
(Akaike information criterion 976 units higher) than the asymp-
totic model, confirming use of our Equation 1 as more
appropriate. Because CD4 recovery in adults is known to be
biphasic [32], we also investigated a model that was the sum of two
asymptotic functions with different proportional rates of recovery,
but were unable to fit it to our data.
Using the fitted model parameters, we can predict CD4
trajectories for children with asymptotic reconstitution starting
ART at different ages and with different CD4 counts. Figure 3A
illustrates predicted trajectories in children starting ART having
reached current (2010) WHO ART initiation criteria aged 2, 6, or
10 y. While the 2-y-old is predicted to recover CD4 count well, the
6- and 10-y-olds show progressively impaired recovery. Thus,
starting ART at older ages appears to impair long-term CD4
count when treatment is initiated at the WHO CD4 count
thresholds for ART initiation, which differ substantially between
children aged ,5 y and .5 y. From Figure 3B it is apparent that
the fixed CD4 threshold for starting ART in children over 5 y old,
while satisfactorily reducing risk of disease progression, increas-
ingly limits the potential for optimal CD4 recovery as the child
approaches adulthood. In early life, however, relatively large
changes in the thresholds for ART initiation have a fairly limited
impact on long-term CD4 count.
Children with Non-Asymptotic CD4 Reconstitution
At ART initiation, the 292 children whose CD4 recovery
differed qualitatively from the asymptotic reconstitution described
above had a median (IQR) age of 7.3 (2.8, 10.7) y and a median
CD4 count of 401 (155, 837) cells/ml. Fitting individual linear
models to CD4-for-age measurements in each of these children
allowed us to identify four subgroups within this population based
on a per-child test of significance for the change in CD4-for-age
over follow-up (Figure 4; Table 3).
Of these 292 children, 23 (8%) (median [IQR] age: 9.2 [6.6,
11.6] y, CD4 count: 281 [89, 1,013] cells/ml, and CD4-for-age:
0.28 [0.08, 0.43], all at ART initiation) had a significant (p,0.05)
decline in CD4-for-age over follow-up. These children’s mean
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CD4-for-age values showed an initial, small response to treatment
in the first few weeks on ART (Figure 4A). After week 12,
however, mean CD4-for-age began to fall, possibly as a result of
treatment failure. Finally, as non-response or failure was detected
and treatment switched to second-line ART, the CD4-for-age
began to recover again. Of note, in univariable tests (Table S1)
these children differed from the larger group with asymptotic CD4
reconstitution only in their older age (p = 0.002). There was no
Figure 2. Modelling CD4-for-age in children showing asymptotic reconstitution. (A) Mean CD4-for-age over time since ART initiation for
914 children with asymptotic CD4 reconstitution. Errors bars give standard error of the mean. Points are shown for times where .20% of children in
this group remained in the trial. Only children participating in a substudy had measurements available at week 4, accounting for the wider error bar.
The numbers of children with measurements available at 0, 4, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, and 228 wk
were 914, 153, 897, 893, 900, 893, 894, 898, 989, 900, 902, 898, 899, 897, 896, 892, 861, 790, 516, 354, and 232, respectively. (B) Population-average
(fixed-effects) ln(CD4-for-age) trajectories predicted by our nonlinear mixed-effects model (Table 2) for ‘‘average’’ HIV-infected children (female,
weight-for-age z-score at ART initiation 22.2) aged 2 (dashed line), 6 (solid line), and 10 (dot-dashed line) y. (C) Predicted CD4-for-age trajectories as
shown in (B), but plotted on the linear scale (i.e., CD4/expected CD4). (D) Correlations between child-level random effects (difference from population
average) in the three model parameters. Each panel refers to correlations between the estimated random effects (differences between child-specific
parameters and the population average) in two of the three parameters int (CD4-for-age at ART initiation), asy (long-term CD4-for-age), and c
(proportional recovery rate). The pair of parameters being considered is identified by the row and column labels in the panels on the diagonal. The
upper-right panels plot the values of the random effects against one another. The lower-left panels give Pearson correlations between the estimated
random effects, with 95% confidence intervals and p-values.
doi:10.1371/journal.pmed.1001542.g002
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Table 1. Characteristics at ART initiation of the two groups of HIV-infected ART-naı¨ve children in the ARROW trial with qualitatively






Female, n (percent) 474 (52%) 136 (49%) 0.13
Age (years) 5.6 (2.3, 9.0) 7.3 (2.8, 10.7) ,0.001
WHO stage, n (percent) 0.72
1 17 (2%) 3 (1%)
2 251 (27%) 83 (30%)
3 514 (56%) 169 (61%)
4 132 (14%) 37 (13%)
CD4 count (cells/ml)a 350 (170, 646) 401 (155, 837) 0.062
CD4-for-age (count/healthy count)a 0.26 (0.14, 0.41) 0.32 (0.14, 0.55) ,0.001
CD4-for-age ln(count/healthy count)a 21.3 (22.0, 20.9) 21.1 (21.9, 20.6) ,0.001
Weight-for-age z-score 22.3 (23.3, 21.3) 22.0 (23.2, 21.0) 0.023
Height-for-age z-score 22.5 (23.5, 21.6) 22.0 (23.1, 21.1) ,0.001
Monitoring randomisation, n (percent) 0.61
LCM 459 (50%) 141 (48%)
CDM 455 (50%) 151 (52%)
First-line ART randomisation, n (percent) 0.024
Arm A 294 (32%) 103 (35%)
Arm B 325 (36%) 79 (27%)
Arm C 295 (32%) 110 (38%)
Data are median (IQR) unless otherwise indicated. p-Values are for Fisher’s exact (WHO stage and first-line ART randomisation), chi-squared (sex and monitoring
randomisation), and Wilcoxon rank sum (continuous variables) tests for a difference between the two groups.
aCD4 count at ART initiation was missing in one child from each group.
doi:10.1371/journal.pmed.1001542.t001
Table 2. Predictors of CD4-for-age after ART for 914 children with asymptotic CD4 reconstitution.
Variable Estimate (95%CI) p-Value
Natural Scale (ln[CD4-for-Age]) Linear Scale (CD4-for-Age)
Intercept (CD4-for-age at ART initiation) 21.59 (21.66, 21.52) 0.20 (0.19, 0.22) ,0.001
Age at ART initiation (per year older) 20.08 (20.10, 20.06) 0.92 (0.91, 0.94) ,0.001
Weight-for-age at ART initiation (per unit z-score higher) 0.16 (0.12, 0.20) 1.17 (1.12, 1.22) ,0.001
Asymptote (long-term CD4-for-age) 20.21 (20.26, 20.16) 0.81 (0.77, 0.85) ,0.001
Age at ART initiation (per year older) 20.048 (20.055, 20.042) 0.95 (0.95, 0.96) ,0.001
Sex (female versus male) 0.11 (0.06, 0.16) 1.11 (1.06, 1.17) ,0.001
ART strategy (Arm B versus Arm A) 0.044 (20.017, 0.105) 1.04 (0.98, 1.11) 0.16
ART strategy (Arm C versus Arm A) 20.14 (20.20, 20.08) 0.87 (0.82, 0.93) ,0.001
c 0.038 (0.036, 0.040) — ,0.001
Results are expressed relative to the reference category (boy, aged 6 y, with weight-for-age z-score 22.2 and randomised to first-line ART strategy Arm A [standard of
care two-NRTI+NNRTI throughout]). Analysis was carried out on the natural logarithm scale (ln[CD4/expected CD4]), but results are reported both on the natural scale
and back-transformed to the linear scale (CD4/expected CD4). Estimated effect sizes of covariates on the baseline (intercept) and the long-term (asymptote) CD4-for-age
are additive on the natural log scale, but multiplicative on the linear scale—for example, a 1-y increase in age is associated with a 20.08 unit lower ln(CD4/expected
CD4) at ART initiation or, equivalently, a CD4/expected CD4 lower by a factor of exp(20.08) = 0.92. Similar effect sizes were seen in univariable models. After adjusting
for the factors shown, there was no additional predictive value on intercept of sex, WHO disease stage 3 or 4, or first-line ART or monitoring strategy; on asymptote of
WHO disease stage 3 or 4, weight-for-age z-score, or monitoring strategy, or on c of age, sex, WHO disease stage 3 or 4, or ART or monitoring strategy (likelihood ratio
tests, p.0.01; further details are given in Table S2). Although weight-for-age was not selected in the backwards selection, likelihood ratio tests to assess additional
predictors on top of the final multivariable model suggested weight-for-age might be a predictor for c (p= 0.003 in likelihood ratio test; estimate 9.3161024 higher per
one-unit increase in weight-for-age [95% CI: 27.0161025, 1.9361023], i.e., faster proportionate recovery speed in those with higher weight-for-age at ART initiation).
However, other effect size estimates were essentially unchanged, and examining closely related covariate models suggests this apparent predictive value may be the
result of overfitting. Thus, the final backwards selection is presented as the final model, as described in the Methods.
doi:10.1371/journal.pmed.1001542.t002
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evidence of between-group differences in other parameters,
including CD4-for-age at ART initiation, and monitoring and
ART strategy randomisations (p.0.08). Clinical progression was
worse than in the asymptotic group: five children (22%) switched
to second-line treatment (none in the first year on ART), 10 (43%)
experienced WHO stage 3 or 4 events, and six (26%) died (all
p,0.001 for comparison to the large asymptotic group; Table S1).
Viral loads were available in 11 children in this group (48%;
median [IQR] 2 [1.5, 3] measurements per child). These children
had poorer virological control than asymptotic responders:
average log-viral load was higher (median [IQR] 4.52 [2.02,
4.76] RNA copies, p = 0.014) and a greater proportion of viral
loads were detectable (1.00 [0.83, 1.00], p,0.001).
79 (27%) of the 292 children (median [IQR] age: 5.5 [2.4, 8.8] y,
CD4 count: 360 [83, 737] cells/ml, and CD4-for-age: 0.28 [0.07,
0.41] at ART initiation) showed continuing improvement in CD4-
for-age with time, characterised by a significant (p,0.05) positive
linear slope (Figure 4B). Like the children with asymptotic
reconstitution, these children’s CD4-for-age increased with time
on ART. Unlike the asymptotic group, however, their CD4-for-age
increased more slowly and continuously over 4–5 y on ART,
although it is possible that CD4 count will plateau in the years
following the last available measurement. These children may be
showing CD4 recovery that is slower for reasons connected to the
mechanism of recovery, and/or to qualitatively different functional
impairments at ART initiation. Compared to the large group with
asymptotic reconstitution (Table S1), there was evidence in
univariate comparisons that these children had lower (less severe)
WHO disease stage (p = 0.0048 for both stage 3 and stage 4 versus
stage 2) and were more likely to be in Arm A and less likely to be in
Arm B (p = 0.024). Other characteristics were similar (p.0.05).
Clinical progression was worse than in the asymptotic group: 21
(27%) children switched to second-line therapy (none in the first
year on ART), and 16 (20%) experienced WHO stage 3 or 4 HIV
events (both p,0.001), although only one child died (Table S1). 60
(76%) of these children had at least one viral load recorded, with a
median (IQR) 5 (2, 9) measurements per child. Their virological
response was similar to that of the asymptotic group: median [IQR]
average log-viral load was 1.96 (1.84, 3.10) (p = 0.70), and the
proportion of viral loads detectable was 0.17 (0.00, 0.53) (p = 0.60).
Linear models in 153 (52%) of the 292 children (median [IQR]
age: 8.1 [3.1, 11.3] y; CD4 count: 479 [230, 980] cells/ml; CD4-
for-age: 0.40 [0.21, 0.66] at ART initiation) showed no evidence of
a significant change in CD4-for-age over the first 4–5 y on ART
(p.0.05) (Figure 4C). These children started ART with a higher
CD4 count and CD4-for-age (both p,0.001 versus those with
asymptotic CD4 reconstitution) and had a small, fast increase in
CD4-for-age in the first few weeks following ART, compatible
with redistribution of memory CD4 T cells. Following this initial
increase, however, CD4-for-age showed no further recovery over
4–5 y of follow-up. Moreover, when ages, weights-for-age, and
CD4 counts in these children were used to predict their long-term
CD4-for-age according to the nonlinear mixed-effects model for
asymptotic reconstitution described above, we found a median
(IQR) predicted long-term CD4-for-age of 20.39 (20.21,
+0.00)—somewhat higher than the steady level observed (around
20.5). While these children did show some response to treatment,
they seemed to be less able to reconstitute CD4 cells in the long
term than the asymptotic group. In addition to their higher CD4-
for-age at ART initiation, in univariate comparisons (Table S1)
these children were older, heavier, and taller than the large group
with asymptotic CD4 reconstitution (p,0.001). Clinical progres-
sion was worse than in the asymptotic responders: 16 children
(10%) switched to second-line therapy (p,0.001), 21 (14%)
experienced WHO stage 3 or 4 HIV events (p = 0.004), and eight
died (5.2%, p,0.001). (ORs for clinical progression are given in
Table S1.) 113 (74%) of these children had viral loads recorded,
with a median [IQR] 4 (2, 7) measurements available per child.
Their virological response was again similar to that of the
asymptotic group: median (IQR) average log-viral load was 2.03
(1.90, 3.18) (p = 0.28), and the proportion of viral loads detectable
was 0.33 (0.00, 0.75) (p = 0.18).
Finally, 37 (13%) of the 292 children (median [IQR] age at
ART initiation: 5.4 [1.8, 9.1] y) had very low baseline CD4 counts
(median [IQR] 130 [22, 671] cells/ml)—and thus low CD4-for-age
(median [IQR] 0.12 [0.02, 0.41])—and #1 CD4 measurements
Figure 3. Predicted long-term CD4 counts in children starting ART at different ages and CD4 levels. (A) CD4 trajectories predicted for
children starting ART having reached WHO CD4 count thresholds at age 2 (dashed line), 6 (dotted line), or 10 (dot-dashed line) y. The thin dashed line
indicates WHO thresholds for ART initiation, and the thin solid line the trajectory in CD4 count with age expected in a healthy child. (B) Expected CD4
count on immunological maturity (estimated at age 20 y) for different ages and CD4 counts at ART initiation. Values at the ends of the grey contour
lines indicate expected adult CD4 count in children starting ART at the ages and CD4 counts given on the horizontal and vertical axes. The black line
indicates the current WHO CD4 thresholds for ART initiation. Grey point markers show the age and fitted CD4 count at ART initiation of the 914
children on whom the model is based. They indicate at which ages/CD4 counts the model has substantial evidence, and where it represents an
extrapolation from the available data.
doi:10.1371/journal.pmed.1001542.g003
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available after ART initiation (Figure 4D). 32 of these children
died, and five were lost to follow-up, early in the trial.
Discussion
At present it is recommended that children initiating ART
should continue treatment for life. Understanding the long-term
impact of treatment initiation at different CD4 counts and ages is
therefore essential to ensure that children reach adulthood with
immune systems as intact as possible. We have conducted an
exploratory study characterising qualitatively and quantitatively
different CD4 responses to ART in a large sample of children
initiating ART. The analysis, which was not pre-planned or
specified in the trial protocol, has allowed us to identify
subpopulations of children who respond in qualitatively different
ways to ART over the long term.
Figure 4. CD4-for-age in children not showing asymptotic reconstitution. Mean CD4 cell count for age with time since ART initiation (error
bars: standard error of the mean) for: (A) 23 children with significant (p,0.05) decreasing CD4-for-age with time; (B) 79 children with significant
(p,0.05) increasing CD4-for-age with time but not fitting the asymptotic model; (C) 153 children with no significant change (p.0.05) in CD4-for-age
with time; and (D) 37 children with only baseline CD4 count available. For comparison to the asymptotic group, grey lines indicate average (fixed-
effects, for a 6-y-old girl with weight-for-age z-score 22.2) CD4-for-age in the 914 children with asymptotic CD4 reconstitution. In (A–C), data points
are shown where .20% of children in each group remained in the trial.
doi:10.1371/journal.pmed.1001542.g004
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The majority of children (76%) had asymptotic CD4 reconsti-
tution following ART initiation, with an initial steep increase in
CD4-for-age that slowed with a half-life of ,18 wk, tending
towards a constant level over the long term of (for a child of
average demographics) ,80% of the CD4 count expected in an
HIV-uninfected child of the same age. CD4-for-age both before
ART and in the long term were higher for children starting ART
at younger ages, and long-term CD4 reconstitution was better in
children with higher CD4-for-age at ART initiation. These results
in resource-limited settings reiterate findings in European cohorts
[19,33], and demonstrate the need for earlier diagnosis in all
settings, the value of testing children at multiple points of access to
healthcare services, and the importance of early availability of
ART at minimum at the recommended thresholds for ART
initiation. Of note, we found no evidence in these more
sophisticated models that CD4 reconstitution (asymptotic or
non-asymptotic recovery, or any model parameter) depended on
whether children received ART with or without CD4 monitoring.
This finding is similar to that of the main randomised comparison
[20] and contrasts with findings in adults, in whom there is
evidence that CD4 monitoring has benefits for long-term immune
reconstitution [9].
Unexpectedly, none of the pre-ART factors considered, nor the
randomised groups, were associated with the parameter char-
acterising speed of proportional CD4 recovery. Although this
might at first appear inconsistent with previous studies showing
faster recovery in younger children [33–35], the measure of
recovery used elsewhere has generally been an absolute one rather
than the proportional rate (c), which we used here. Thus, absolute
reconstitution may be faster in younger children in that a given
increase in CD4 count or percentage takes less time, but a given
proportion of the total long-term improvement achieved may still
occur in the same time, regardless of age. Nonetheless, we did find
significant inter-individual variability in proportional recovery rate
that was unexplained by the pre-ART factors studied. Genetic
differences between children and/or viral strains may be one
explanation for this, and the qualitative composition of the CD4
count when ART began—for example, the percentages of
activated and proliferating cells—may also play a role.
As in European/US children, we found that the asymptotic
model was a better fit to the data from African children than the
two-slope linear mixed-effects model that is optimal in adults [18].
This finding adds further weight to the hypothesis that CD4
recovery in children differs qualitatively and mechanistically from
that in adults, perhaps reflecting greater involvement of the naı¨ve
T cell pool and greater dependence on thymopoiesis; this finding is
supported by the difference in the impact of CD4 monitoring on
long-term reconstitution in adults [9] compared to children [20].
Some of the conclusions from adult studies do, however, apply also
in children. For example, like the children studied here, adults
with low CD4 counts at ART initiation have been observed to
have generally lower CD4 counts 3 y later [36].
Using parameters obtained from the nonlinear mixed-effects
model for asymptotic CD4 reconstitution, we were able to predict
CD4 trajectories for children starting ART at different ages and
with different CD4 counts, reflecting the response that would be
expected from the majority of children initiating ART. Qualita-
tively, our findings are similar to those obtained in previous work
on European and Brazilian children [19], but the far larger
numbers in the present study now provide much greater certainty
Table 3. Characteristics at ART initiation of four subgroups of HIV-infected ART-naı¨ve children who did not show asymptotic CD4-
for-age reconstitution on long-term ART (n = 292).
Characteristic
CD4-for-Age
Decreasing (p , 0.05)
(n = 23)
CD4-for-Age




(p . 0.05) (n = 153)
#2 Measurements
(n = 37) p-Value
Female, n (percent) 12 (52%) 40 (51%) 68 (44%) 16 (43%) 0.59
Age (years) 9.2 (6.6, 11.6) 5.5 (2.4, 8.8) 8.1 (3.1, 11.3) 5.4 (1.8, 9.1) 0.009
WHO stage, n (percent) 0.16
1 0 (0%) 1 (1%) 2 (1%) 0 (0%)
2 6 (26%) 32 (41%) 39 (25%) 6 (16%)
3 13 (57%) 39 (49%) 100 (65%) 17 (46%)
4 4 (17%) 7 (9%) 12 (8%) 14 (38%)
CD4 count (cells/ml)a 281 (89, 1013) 360 (83, 737) 479 (230, 980) 130 (22, 671) 0.016
CD4-for-age (count/healthy count)a 0.28 (0.08, 0.43) 0.28 (0.07, 0.41) 0.40 (0.21, 0.66) 0.12 (0.01, 0.34) 0.002
CD4-for-age ln(count/healthy count)a 21.3 (22.5, 20.9) 21.3 (22.7, 20.9) 20.9 (21.6, 20.4) 22.1 (24.2, 21.1) 0.002
Weight-for-age z-score 21.7 (22.8, 21.4) 22.0 (23.2, 20.8) 21.8 (22.8, 20.8) 23.5 (25.0, 22.4) 0.55
Height-for-age z-score 22.1 (23.4, 21.1) 22.3 (23.3, 21.0) 21.9 (22.8, 21.2) 22.7 (23.4, 21.4) 0.73
Monitoring randomisation, n (percent) 0.33
LCM 7 (30%) 38 (48%) 71 (46%) 25 (68%)
CDM 16 (70%) 41 (52%) 82 (54%) 12 (32%)
First-line ART randomisation, n (percent) 0.14
Arm A 7 (30%) 35 (44%) 48 (31%) 13 (35%)
Arm B 10 (43%) 20 (25%) 42 (27%) 7 (19%)
Arm C 6 (26%) 24 (30%) 63 (41%) 17 (46%)
Data are median (IQR) unless otherwise indicated. p-Values are for Fisher’s exact (categorical variables) or Kruskal-Wallis (continuous variables) tests for a difference
between the four groups.
doi:10.1371/journal.pmed.1001542.t003
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and also demonstrate that factors such as co-infection burden,
malnutrition, and trial recruitment criteria do not appear to cause
large differences in the CD4 response to ART. From Figure 3B,
predicted CD4 count at age 20 y (i.e., in adulthood) can be
estimated for every combination of age and CD4 count at ART
initiation. Although our predictions extrapolate the data forward
in time, the wide age and CD4 range at ART initiation, and the
stability of results compared to analysis through 3 y, suggest that
the extrapolations are reasonable. Nevertheless, further analysis of
long-term CD4 response in adolescents will be important as
validation. The figure shows how starting ART at the same CD4
count but at progressively older age is increasingly detrimental to
long-term immunological health. For example, to achieve a CD4
count of .700 cells/ml at 20 y of age, children under 8 y need to
start ART with a CD4 count .223 cells/ml, but a 10-y-old would
need to start before CD4 count falls below 347 cells/ml, and a 12-
y-old before reaching 557 cells/ml. In contrast, a 2-y-old would
need only a CD4 count .96 cells/ml, and a 5-y-old, CD4 count
.130 cells/ml. To optimise immune reconstitution when children
reach adulthood, our findings suggest that ART may be warranted
in vertically HIV-infected children who are still ART-naı¨ve at ages
over 10 y, regardless of CD4 count. In young children, however,
current guidelines designed to minimise risk of disease progression
also preserve the potential for good CD4 counts in the long term.
Clearly, the aim of an ART strategy for an HIV-infected child is
not limited to maximising CD4 count, but is a matter of balancing
overall immunological health—encompassing lymphocyte dynam-
ics, population structure and receptor diversity, and the effective-
ness of the immune response overall—against short-term side
effects, long-term toxicity, regimen durability (particularly in
resource-limited settings where frequently only two regimens are
available), cost, treatment adherence, and social factors. Even a
CD4 count as low as 500 cells/ml is above the 2.5th centile for
CD4 count in a population of healthy adults, raising questions
about the appropriateness of aiming for a long-term CD4 count as
high as, for example, 700 cells/ml, especially where multiple other
factors might argue against ART. However, even relatively small
reductions from normal CD4 counts in HIV-infected patients have
been associated with increased risk of cardiovascular disease and
malignancies [37–39]. We also note that our predictions are of
CD4 response expected on average in HIV-infected children
starting ART. While an increase in the CD4 count threshold for
ART initiation might result in an only marginally higher long-
term count for the ‘‘average’’ child, the shift in the whole
distribution of CD4 counts to higher levels results in fewer children
being likely to experience lower counts.
Interestingly, we found slightly, but significantly, lower long-
term CD4-for-age values in children receiving three-NRTI
maintenance (including zidovudine) (Arm C), despite no differ-
ences in CD4 cell percentage over the long term [20] and no
difference in the proportion achieving asymptotic response
compared to standard two-NRTI+NNRTI treatment. One
explanation is the known haematological toxicity of zidovudine,
which may modestly suppress all components of the white blood
count, leaving proportionate (percentage) recovery unchanged.
Whether these small differences in long-term asymptote (,13%
reduction compared to Arm A) are clinically important is
unknown. However, we also found that children randomised to
Arm B (four-drug, two-class induction followed by standard two-
NRTI + NNRTI maintenance) were more likely to have
asymptotic than non-asymptotic reconstitution profiles, a novel
finding not identified by the standard comparison of mean
responses [20]. This supports the potential of enhanced initial
treatment to improve long-term CD4 responses.
Approximately one-quarter of children did not have asymptotic
CD4 reconstitution. The fact that subgroups within the population
had very different patterns of reconstitution, and varied in both
CD4 count and age at ART initiation, highlights the issue of
modelling one single population mean response across qualita-
tively different types of reconstitution. Those who had a constant
or increasing CD4-for-age following ART had a higher CD4-for-
age at ART initiation. We suggest that the differences between
these children and those showing asymptotic reconstitution may
arise from different reconstitution mechanisms, or qualitatively
different CD4 T cell populations at ART initiation. Other children
whose CD4 count declined on ART had similar CD4-for-age at
ART initiation but were older than the group with asymptotic
CD4 reconstitution. Children with #2 CD4 measurements after
ART initiation had had very low CD4-for-age values when ART
was begun; most died early in the trial. Factors affecting
reconstitution profiles in these 292 children may have included
clinical factors, adherence, and viral dynamics, and investigating
these and other factors/mechanisms influencing CD4 recovery in
children with atypical CD4 responses will provide interesting
directions for further research. Our findings regarding the
different CD4 reconstitution groups should also be validated in
independent studies.
Children in each of the non-asymptotic recovery groups
experienced more regimen switching, WHO disease stage 3 and
4 events, and deaths than the large group of asymptotic
responders. While this is an interesting and important observation,
it does not allow any conclusions about causation to be drawn. On
the one hand, it is possible that more frequent clinical events might
have impaired children’s CD4 recovery and led to their different
reconstitution profiles. Equally, however, since children in the
non-asymptotic groups had CD4-for-age values below those of the
asymptotic responders at almost all time points (Figure 4), it is
unsurprising that they experienced more regimen switching,
clinical events, and deaths. What can be stated is that, since
logistic regression models showed little absolute difference in age-
corrected CD4 counts between the two groups at ART initiation,
the CD4 count when ART begins does not explain the substantial
difference between asymptotic and non-asymptotic recovery.
One of the limitations of this study was the lack of systematic
viral load measurements, which have only been retrospectively
assayed in subsets of children at restricted time points [20] (further
work ongoing). Previous work suggests that viral loads before ART
are likely to predict CD4 count at ART initiation (though not in
the long term) [19], and that joint models incorporating CD4
count and viral load are superior to univariate models of CD4
response only [40]. In the absence of systematic viral load
measurements on all children, we were not able to assess
conclusively whether patterns of viraemia could be contributing
to the patterns of CD4 response. Nevertheless, the incomplete
results that were available suggested that the children with falling
CD4-for-age (Figure 4A, 23 children) had poorer virological
control than the group with asymptotic recovery. However,
children with slowly increasing (Figure 4B, 79 children) or constant
(Figure 4C, 153 children) CD4-for-age had similar virological
responses to the asymptotic responders. There were examples of
viral rebound in all response groups. Hence, although virological
control may be an important factor for children with falling CD4
counts, it does not appear to explain the differences in CD4
responses between the asymptotic group and the two major non-
asymptotic groups.
A limitation of the modelling approach is that uncertainty as to
children’s group allocation to asymptotic or non-asymptotic
recovery is not accounted for. This problem is illustrated by the
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observation that an earlier analysis—of data up to 1 April 2011
(i.e., missing the last year of the trial)—reversed the allocations of a
small number of children. The uncertainty in allocation could be
modelled using mixture models or latent class models, and this will
be an important further step in developing this kind of analysis.
However, the robustness of allocation in the vast majority of
children when data from the last year of the trial were included or
excluded suggests it is unlikely that failing to model the uncertainty
has materially affected our conclusions. In previous work, we fitted
a nonlinear mixed-effects model with an asymptotic recovery
function to a whole cohort of HIV-infected children starting ART.
In spite of modelling recovery as asymptotic in all children, the
same conclusion was reached: that age affects CD4 count both
before ART and in the long term, and that there is an additional
correlation between unexplained differences in counts at ART
initiation and in the long term [19]. Thus, although parameter
estimates might be revised slightly by a more rigorous model, it
seems likely that our conclusions would remain unchanged. The
allocation of children to asymptotic versus non-asymptotic
recovery groups also raises a problem with predictions: while
predictions like those illustrated in Figure 3B are helpful for
children who will go on to experience asymptotic recovery, they
are less relevant to those with different recovery profiles. This is a
particular example of a general and widespread problem with
using population-level responses to inform treatment guidelines. In
this context, at the level of individual children, it highlights the
challenge of identifying baseline predictors of non-asymptotic
recovery so that those children can be treated differently.
In conclusion, our analysis of data from a large cohort of HIV-
infected, ART-naı¨ve African children initiating ART provides
important information to inform clinical practice by considering
long-term CD4 reconstitution in response to therapy in resource-
limited settings, and the roles of age and CD4 count at ART
initiation in determining this response. Given increased availability
of simpler ART formulations and regimens for children, we have
reinforced the importance of considering long-term immunological
health, as well as short-term disease progression, in the decision to
initiate ART and the development of treatment guidelines. Our
data suggest that even though the short-term risks of morbidity and
mortality are greater in younger untreated children, survivors have
excellent potential for immune reconstitution when they initiate
ART. In contrast, whilst not subject to the same immediate risks of
disease progression/death, older children who wait to initiate ART
may never reconstitute immunologically to the same degree. The
current CD4 count thresholds for ART initiation are predominantly
based on these short-term risks, and in older children could lead to
delays in ART administration that might compromise immune
reconstitution in adulthood.
Our results indicate that although younger ART-naı¨ve children
are at high risk of disease progression, provided they start ART
following current WHO/Paediatric European Network for Treat-
ment of AIDS/US Centers for Disease Control and Prevention
guidelines, they have good potential for achieving high CD4 levels
in later life. However, to attain maximum immune reconstitution
in older children, particularly those .10 y, ART may need to be
initiated regardless of CD4 cell count. The approach taken in this
study to characterise long-term immunological outcomes has the
potential, by identifying qualitatively different CD4 recovery
profiles, to improve our understanding of the factors that
determine children’s CD4 counts on ART and provide input into
future management guidelines in both resource-rich and resource-
limited settings.
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Editors’ Summary
Background. Worldwide, about 3.3 million children under
15 years old are infected with HIV, the virus that causes AIDS.
More than 90% of these children live in sub-Saharan Africa,
where nearly 600 children become infected with HIV every
day, usually acquiring the virus from their mother during
pregnancy, birth, or breastfeeding. HIV gradually reduces the
numbers of CD4 lymphocytes in the immune system, leaving
infected individuals susceptible to other infections. HIV
infection can be kept in check but not cured with
antiretroviral therapy (ART)—cocktails of drugs that have
to be taken every day throughout life. ART reduces the
amount of virus in the blood (viral load), which allows the
immune system to recover (long-term immune reconstitu-
tion). Unfortunately, ART is very expensive, but concerted
international efforts over the past decade mean that about a
third of children who need ART are now receiving it,
including half a million children in sub-Saharan Africa.
Why Was This Study Done? World Health Organization
(WHO) guidelines recommend initiation of ART at age-related
CD4 cell count thresholds based on the risk of short-term
disease progression. The guidelines recommend that all HIV-
positive children under two years old begin ART as soon they
receive a diagnosis of HIV infection. For children aged 2–5
years, ART initiation is recommended once the CD4 count
drops below 750 cells/ml blood, whereas for older children the
threshold for ART initiation is 350 CD4 cells/ml. Because of
improved ART coverage, many more HIV-infected children
now survive into adulthood than in the past. It is therefore
important to know how the timing of ART initiation in
childhood affects long-term immune reconstitution. Unfortu-
nately, although several studies have examined the effect of
ART on immune reconstitution in adults, the results of these
studies cannot be extrapolated to children because of age-
related differences in immune reconstitution. In this cohort-
based modelling study, the researchers investigate long-term
CD4 recovery in a cohort (group) of HIV-infected children
initiating ART in Uganda and Zimbabwe, and present
statistical models that predict patterns of long-term CD4
status based on age and CD4 count at ART initiation.
What Did the Researchers Do and Find? To investigate
long-term CD4 reconstitution in children, the researchers
used CD4 counts collected during the ARROW trial, a study
designed to investigate monitoring strategies during first-
line ART in 1,206 HIV-positive children. In three-quarters of
the children, CD4 reconstitution following ART initiation was
asymptotic—CD4 counts increased rapidly immediately after
ART initiation, then slowed before eventually reaching a
constant level of about 80% of the CD4 count expected in an
uninfected child of the same age. Using a nonlinear mixed-
effects statistical model that fitted this pattern of immune
reconstitution, the researchers predicted CD4 trajectories for
children starting ART at different ages and with different CD4
counts. Higher long-term counts were predicted for children
starting ART earlier and with higher CD4 counts. Thus, to
achieve a CD4 count greater than 700 cells/ml at age 20 years,
CD4 counts of at least 96 cells/ml, 130 cells/ml, and 557 cells/
ml are needed for children aged two, five, and 12 years,
respectively, when they initiate ART. Qualitatively distinct
reconstitution patterns were seen in the remaining children
in the study.
What Do These Findings Mean? These findings suggest
that young HIV-positive, ART-naı¨ve children can achieve
high CD4 counts in later life, provided ART is initiated as
recommended in the current WHO guidelines. However,
the recommended CD4 count thresholds for ART initia-
tion are unlikely to maximize immune reconstitution in
treatment-naı¨ve children over ten years old. Rather, these
findings suggest that ART initiation should be considered
in these older children when their CD4 count is still
high—even though they have a low risk of immediate
disease progression—in order to achieve higher long-
term CD4 levels. The omission of viral load measurements
in the researchers’ model may limit the accuracy of these
findings. Moreover, although the predictions made by the
model apply to children who will go on to experience
asymptotic recovery, they are less relevant to those with
different recovery profiles, who cannot currently be
accurately identified. Further exploration of the immuno-
logical mechanisms underlying the CD4 recovery profiles
described here should improve our understanding of the
factors that determine the response of HIV-positive
children to ART and provide information to guide the
management of HIV infections in children.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001542.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N NAM/aidsmap provides basic information about HIV/AIDS
and summaries of recent research findings on HIV care and
treatment
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV and AIDS in Africa and on HIV infection in
children (in English and Spanish)
N The UNAIDS World AIDS Day Report 2012 provides up-to-
date information about the AIDS epidemic and efforts to
halt it; the UNAIDS’s 2013 Progress Report on the Global
Plan provides information on progress towards eliminating
new HIV infections among children by 2015
N The World Health Organization provides information about
universal access to AIDS treatment (in several languages);
its 2010 guidelines for ART in infants and children can be
downloaded
N Information about the ARROW trial is available
N Personal stories about living with HIV/AIDS, including
stories from young people infected with HIV, are available
through Avert, through Nam/aidsmap, and through the
charity website Healthtalkonline
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